Expert articles on effective weight loss, Mounjaro, and peptides
133 articles
Cagrilintide, tirzepatide, and semaglutide work through different receptors. We break down the science, compare research results, and show the selection algorithm.
Cagrilintide (amylin) side effects: why 41% initial nausea drops to 12% in 4 weeks, comparison with Mounjaro and Ozempic, 6 practical tips.
Cagrilintide (Amylin) is a long-acting analog of the amylin hormone. It works through a different pathway than Ozempic or Mounjaro. CagriSema showed -22.7% weight loss over 68 weeks.
How to properly increase retatrutide dose to avoid side effects and achieve maximum results: practical step-by-step protocol.
Triple agonist vs dual agonist: Understanding how Retatrutide differs from Mounjaro and which product suits each person for weight management.
What to expect on Retatrutide, side effect profile, and how the triple mechanism changes the experience compared to Mounjaro and Ozempic.
Ready to lose weight with Mounjaro?
Free specialist consultation — we'll select the right dose and program for you
The first drug to activate three receptors simultaneously: GLP-1, GIP, and glucagon. Minus 24% weight in 48 weeks — but should you start with this one?
Ozempic isn't just safe. The SELECT study proved it reduces cardiovascular events by 20%. We address all concerns with data.
Ozempic and Wegovy are both semaglutide from Novo Nordisk. The difference is in dose and indications. Why only Ozempic is available in Ukraine and whether it's sufficient for effective weight loss.
GLP-1 pipeline full of innovations: orforglipron, survodutide, amycretin, CagriSema. Understanding when they'll arrive and why you shouldn't wait for the 'perfect' drug.
Anastasiia Shapoval
Why GLP-1 medications change alcohol response, how much is safe to drink, and why half of clients voluntarily give up alcohol.
Anastasiia Shapoval
Retatrutide is the first triple GLP-1+GIP+glucagon agonist with -24.2% weight loss results. How the third receptor works and where to try it in Ukraine.
Anastasiia Shapoval